Effective treatment options for surfactant therapy in acuterespiratory distress syndrome and coronavirus disease 2019 have not beenestablished. To conduct preclinical studies in vitro and in vivo to evaluateefficiency, particle size, dosing, safety, and efficacy of inhaled surfactantusing a breath-synchronized, nebulized delivery system in an establishedacute respiratory distress syndrome model.
